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Abst rac t
Background and purpose: Inflammation plays a prominent
role in Alzheimer disease (AD) pathogenesis. Interleukin-6
(IL-6), a pro-inflammatory cytokine, and some genetic varia -
tions in the IL-6 gene have been reported to be associated
with a risk of AD. However, the results of the conducted
studies are equivocal.
Material and methods: We genotyped IL-6 (–174 C/G) and
apolipoprotein E gene (APOE) common polymorphisms in
a large case-controlled study in a Polish population. We
included 361 patients aged ≥ 65 years with AD (mean age
75.8 ± 5.3 years, 232 females [64.3%]) and 200 controls
(75.3 ± 7.4 years; 119 females [59.5%]), without any neu-
rological deficit, cognitive complaints or history of neuro-
logical diseases. The IL-6 polymorphism was genotyped
using TaqMan SNP allelic discrimination by means of an
ABI 7900HT (Applied Biosystems, Foster City, CA). 
Results: The distribution of the IL-6 (–174 C/G) genotypes
was similar to that in the controls (AD: C/C = 15.79%, C/G
= 51.25%, G/G = 32.96% vs. controls: C/C = 21.50%,
C/G = 45.50%, G/G = 33.0%, p > 0.05). Our study con-
firms previous reports that APOE 4 is strongly related to the
risk of AD (OR = 6.17; 95% CI: 4.01-9.49). APOE status
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St reszczenie
Wstêp i cel pracy: Choroba Alzheimera jest najczêstsz¹ cho-
rob¹ zwyrodnieniow¹ oœrodkowego uk³adu nerwowego. Pato-
geneza choroby nie zosta³a poznana; uwa¿a siê, ¿e procesy
zapalne odgrywaj¹ istotn¹ rolê w jej rozwoju. Interleukinê 6
(IL-6), bêd¹c¹ cytokin¹ prozapaln¹, oraz niektóre polimor-
fizmy genu IL-6 wi¹¿e siê ze wzrostem ryzyka zachorowa-
nia na chorobê Alzheimera, jednak wyniki badañ nad tym
zagadnieniem nie s¹ jednoznaczne. 
Materia³ i metody: Do badania w³¹czono 361 chorych ≥ 65.
roku ¿ycia [œrednia wieku 75,8 ± 5,3 roku, 232 kobiety
(64,3%)] oraz 200 osób z grupy kontrolnej [75,3 ± 7,4 roku;
119 kobiet (59,5%)] bez skarg na zaburzenia funkcji poznaw-
czych, chorób neurologicznych w wywiadzie i deficytu 
neurologicznego w badaniu klinicznym. Osoby chore i zdro-
we by³y rasy kaukaskiej. Oznaczono polimorfizm IL-6
(–174 C/G) oraz apolipoproteiny E (APOE). Polimorfizm
pojedynczego nukleotydu –174 C/G genu IL-6 zosta³ ozna-
czony za pomoc¹ sond TaqMan na urz¹dzeniu ABI 7900HT
(Applied Biosystems, Foster City, CA).
Wyniki: Rozk³ad genotypu IL-6 (–174 C/G) u osób z cho-
 rob¹ Alzheimera i w grupie kontrolnej by³ podobny (choroba
Alzheimera: C/C = 15,79%, C/G = 51,25%, G/G = 32,96%;
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Introduction 
Alzheimer disease (AD) is the most common neu-
rodegenerative disease. The main pathological feature
of AD is the presence of abnormally accumulated pro-
teins and loss of neurons in specific brain regions [1].
The progressive neurodegenerative process in AD is
accompanied by chronic inflammation, including acti-
vation of microglia and astrocytes that express pro-
inflammatory cytokines [2]. 
Several lines of evidence point to the involvement of
interleukin-6 (IL-6) in pathogenesis of AD. Both experi -
mental and clinical data indicate that brain expression
[3-6], plasma [7-11] and cerebrospinal fluid levels [12]
of IL-6 may affect plaque formation, cognitive decline
or dementia both in cross-sectional and longitudinal 
follow-up studies.
The IL-6 gene in humans is located on chromosome 7
(7p21). The (–174 C/G) polymorphism in the promot-
er region of the IL-6 gene was reported to affect the 
IL-6 gene transcription rates [13] and IL-6 plasma 
levels in AD patients [13,14], implicating its role in
development of AD.
Studies analysing a link between the IL-6 
(–174 C/G) polymorphism and risk of AD in different
ethnic groups have yielded conflicting results; some
found an association [15-19] whereas others did not
[14,20-28]. The aim of the present study was to inve -
stigate a possible association between the IL-6
(–174 C/G) polymorphism and the risk of AD in a case-
control study in a large Polish population sample. 
Material and methods 
Participants
We studied a total sample of 561 subjects. The AD
group consisted of 361 patients who were at least 
65 years old at the onset of the disease (mean age, 75.8
± 5.3 years, 232 females [64.3%]) and had no family
history of AD. Onset was defined as age at which me -
mory loss or change in behaviour was first noted. The
patients were recruited from the Outpatient Memory
Clinic, Neurology Department, University Hospital in
Krakow (58.5%) and the Department of Neurodege -
nerative Disorders, Medical Research Centre, Polish
Academy of Sciences in Warsaw. Clinical diagnosis of
probable AD was made according to the National Insti-
tute for Neurological and Communicative Disorders
and Stroke and the Alzheimer’s Disease and Related
Disorders Association criteria [29]. The evaluation
included medical, neurological and neuropsychological
examination, interview with a close informant, labora-
tory testing and computed tomography or magnetic 
resonance imaging. The details of patients’ evaluation
are described comprehensively elsewhere [30].
The control group included 200 unrelated caregivers
or volunteers (mean age: 75.3 ± 7.4 years; 119 females
[59.5%]), consecutively recruited from the population
of Krakow. They had no apparent neurological disease
or psychiatric syndrome, cerebrovascular disease or
severe functional limitations and obtained > 26 points
on the Mini-Mental State Examination (MMSE) [31].
Controls and AD patients were Caucasian and of East-
ern European descent. 
All participants gave informed consent and the study
was approved by the Local Ethical Committee.
Genetic analyses 
The IL-6 promoter (–174 C/G) and the APOE
common polymorphism were studied. DNA was ex -
tracted from leucocytes using the standard protocol. 
The IL-6 polymorphism was genotyped using TaqMan
SNP allelic discrimination by means of an ABI 7900HT
(Applied Biosystems, Foster City, CA). The APOE
did not affect the distribution of the studied IL-6 polymor-
phism. 
Conclusion: IL-6 (–174 C/G) polymorphism is not a risk
factor for late onset AD in a Polish population.
Key words: Alzheimer disease, interleukin-6, APOE, poly-
morphism, risk factor, Polish population.
grupa kontrolna: C/C = 21,50%, C/G = 45,50%, G/G =
33,0%, p > 0,05). Badanie potwierdzi³o, ¿e APOE 4 jest
czynnikiem ryzyka choroby Alzhei mera (OR = 6,17; 
95% CI: 4,01–9,49). Polimorfizm APOE nie mia³ wp³ywu
na rozk³ad polimorfizmu IL-6. 
Wniosek: Polimorfizm IL-6 (–174 C/G) nie jest czynnikiem
ryzyka choroby Alzheimera o póŸnym pocz¹tku w populacji
polskiej.
S³owa kluczowe: choroba Alzheimera, interleukina 6, APOE,
polimorfizm, czynniki ryzyka, populacja polska.
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–174 C/G polymorphism of IL-6 gene and AD
polymorphisms were genotyped by a PCR-based assay
simultaneously utilizing two distinct restriction enzymes
(HaeII and AflIII enzymes were applied).
Statistical analyses 
The genotype and allele frequencies of the IL-6 poly-
 morphism were compared between cases and controls
using the χ2 test (SPSS for Windows, v.10.0). The Hardy-
Weinberg equilibrium was verified for all tested popu-
lations. Adjusted odds ratios (OR) with 95% confidence
intervals (CI) were estimated by logistic regression, 
controlling for APOE 4 carrier status, gender, and age.
The level of significance was set at p < 0.05. 
To achieve 80% power in this study, with 361 cases
and 200 controls, at 0.05 alpha error the effect of the
IL-6 allele would have to be OR > 1.44.
The results of our study were combined with those
of the previous studies assessing the significance of the
studied polymorphism using a fixed or random effect
model with the software MIX version 1.7.
Results 
Genotype distributions of the IL-6 (–174 C/G)
polymorphism and the APOE gene common polymor-
phism in both groups were in Hardy-Weinberg equi-
librium. The frequencies of the G/G genotype and the
G allele were similar in AD patients and controls and
the difference did not reach significance (p = 0.20 and
0.30, respectively). Table 1 shows the IL-6 genotype
and allele distribution in patients and controls. 
The genotype with the APOE 4 allele was found in
54.2% of the studied patients and in 16.0% of the con-
trols (p < 0.001). The possession of at least one E4 allele
was associated with a risk of AD in univariate analysis
(OR = 6.16, 95% CI: 4.01-9.49, p < 0.0001) and after
adjustment for gender and age at disease onset
(OR = 6.17, 95% CI: 4.01-9.50, p < 0.0001). We
examined the distribution of the IL-6 genotype and
allele frequencies after stratification of the data by
APOE 4 carrier status. We found that the distribution
of the studied polymorphism did not differ between the
carriers and non-carriers of the APOE 4 allele (Table 1). 
After pooling the results of our study with the results
of the 14 previous studies in Caucasians available in the
AlzGene database (http://www.alzgene.org/meta.asp?
geneID=53) we found that the studied polymorphism
did not affect the risk of developing AD when the signifi -
cance of the C vs. T allele was considered (OR = 1.0012;
95% CI: 0.9355-1.0714, z-statistic = 0.0334, p = 0.97). 
IL-6 (–174 C/G) genotypes AD patients Controls χ2 – statistic p-value
(N = 361) (N = 200) value
CC 57 (15.80%) 43 (21.50%) 3.21 (df = 2) 0.20
GC 185 (51.25%) 91 (45.50%)
GG 119 (32.96%) 66 (33.0%)
IL-6 (–174 C/G) allele 
C 299 (41.41%) 177 (44.25%) 0.84 (df = 1) 0.30
G 423 (58.59%) 223 (55.75%)
APOE (ε2/3/4) genotypes
2/2 0 (0%) 2 (1.0%) 89.25 (df = 5) < 0.0001* 
2/3 19 (5.26%) 24 (12.00%)
3/3 147 (40.72%) 142 (71.00%)
2/4 8 (2.22%) 7 (3.50%)
3/4 162 (44.88%) 25 (12.50%)
4/4 25 (6.93%) 0 (0%)
2/2 or 2/3 or 3/3 166 (45.98%) 168 (81.0%) 77.21 (df = 1) < 0.0001
2/4 or 3/4 or 4/4 195 (54.02%) 32 (19.0%)
Table 1. IL-6 (–174 C/G) and APOE (ε2/3/4) genotype and allele frequencies for patients with Alzheimer disease (AD) and controls
*Cochran-Armitage Trend Test; Z = –7.99
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Discussion 
We did not find any evidence of an association
between the IL-6 (–174 C/G) polymorphism and late
onset AD in the Polish population sample. The distri -
bution of the studied polymorphism was similar to that
observed in countries at the same geographic latitude, but
different when geographical longitude was consi dered
[14]. Our study confirms previous reports that APOE 4
is strongly related to the risk of AD (OR = 6.17; 
95% CI: 4.01-9.49) [32,33]. APOE status did not affect
the distribution of the studied IL-6 polymorphism.
Previous studies (12 case-control and 2 prospective
studies) assessing the connection between the IL-6 poly-
morphism and the risk of AD brought equivocal results.
Faltraco et al. [16] reported risk reducing association
of the IL-6 C allele in AD. Pola et al. [18] found that
the G/G polymorphism was associated with increased
risk of AD. In other studies on Italian populations the
IL-6 C allele increased the risk of AD [12,14], the C/C
genotype increased the risk of AD in women [17], and
the G/G genotype was lower in AD than in healthy con-
trols [15]. However, other studies did not find an asso-
ciation between the IL-6 polymorphism and AD [14,
20-28].
Differences in study design and the geographical
variations of IL-6 frequency may in part explain the dif-
ferent patterns of association between this polymorphism
and AD in various studies. In most studies patients with
AD had neuropsychological examination but in controls
no test battery was used, apart from MMSE; therefore
some cases with incipient AD might have been includ-
ed. Moreover, all studies published to date analysing the
role of the IL-6 (–174 C/G) polymorphism in AD have
been underpowered. That is why we performed a meta-
analysis assessing the significance of the studied poly-
morphism on all available data from 3107 AD patients
and 10 014 controls. This meta-analysis, however, was
not able to show the significance of the IL-6 (–174 C/G)
polymorphism for the risk of AD.
Conclusion
IL-6 (–174 C/G) polymorphism is not a risk factor
for late onset AD in a Polish population.
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